TRAW

Business Context and Reporting Period

Traws Pharma, Inc. (TRAW) is a clinical-stage biopharmaceutical company focused on respiratory viral diseases and oncology. This Form 10-Q covers the quarterly period ended June 30, 2025. The Company operates as a non-accelerated filer and a smaller reporting company. Following a merger with Trawsfynydd Therapeutics in April 2024, the Company's portfolio includes tivoxavir marboxil (influenza/bird flu), ratutrelvir (COVID-19), narazaciclib (oncology), and rigosertib (oncology).

Key Financial Metrics

Note: The net income for the six months ended June 30, 2025, is primarily driven by a non-cash gain of $26.66 million from the change in fair value of warrant liabilities.

Material Changes vs. Prior Period

• Revenue Surge: Revenue increased to $2.73 million for the quarter (from $57,000 in Q2 2024) due to the recognition of $2.73 million in previously deferred revenue following the termination of a license agreement with Symbio Pharmaceuticals on April 17, 2025.
• Operating Expenses: Total operating expenses decreased significantly to $3.98 million in Q2 2025 compared to $123.41 million in Q2 2024. The prior year included a one-time, non-cash charge of $117.46 million for acquired in-process research and development (IPR&D) related to the Trawsfynydd merger.
• Warrant Liability: The Company recorded a gain of $26.66 million for the six months ended June 30, 2025, due to the reclassification of warrant liabilities to equity and changes in fair value. This contrasts with no such activity in the prior year.
• Liquidity: Cash and cash equivalents decreased from $21.34 million at December 31, 2024, to $13.08 million at June 30, 2025, reflecting a net cash outflow of $8.26 million for the six-month period.

Outlook, Risks, and Management Commentary

• Going Concern: Management states that substantial doubt exists regarding the Company's ability to continue as a going concern. With $13.08 million in cash, the Company does not have sufficient funds to support operations for more than one year from the filing date.
• Financing Needs: The Company plans to explore dilutive and non-dilutive funding sources, including equity financings (via an At-The-Market offering) and strategic alliances. Failure to secure capital would materially adversely affect operations.
• Regulatory Progress: The Company is engaging with the FDA regarding the "Animal Rule" for tivoxavir marboxil (bird flu) and has deferred a Phase 2 study due to recruitment challenges. A Phase 2 study for ratutrelvir (COVID-19) is planned for the Southern Hemisphere.
• Internal Controls: The Company disclosed material weaknesses in internal controls over financial reporting as of December 31, 2024, which remained unremediated as of June 30, 2025. Disclosure controls and procedures were deemed ineffective.
• Legal Contingency: The Company is involved in arbitration with a former executive regarding severance claims, with a potential loss range of $0 to $1.5 million.

Investor Verification Checklist

• Cash Runway: Verify the specific timeline for cash depletion and the status of any pending financing agreements.
• Warrant Liability Reclassification: Confirm the details of the warrant amendments that led to the $26.66 million non-cash gain and the remaining liability balance.
• Revenue Sustainability: Assess whether the $2.73 million revenue recognized from the Symbio termination is a one-time event or indicative of future recurring revenue.
• Internal Control Remediation: Review the progress of the remediation plan for material weaknesses in internal controls to ensure future financial reporting reliability.
• Related Party Transactions: Review the extent of R&D expenses paid to related parties (ChemDiv, Viriom, Expert Systems) totaling approximately $2.6 million for the six months ended June 30, 2025.